Founded in 1849, Pfizer, based in New York for more than 160 years, is currently the world's largest R&D-based biopharmaceutical company. Its products cover a wide range of potential therapeutic and health fields including chemical drugs, biological agents, vaccines, health drugs, etc., and its world-leading research and development and production capacity.
Although it is the largest pharmaceutical company in the world, it will actually face a bottleneck in development. In order to seek growth, it is currently struggling to struggle. Undoubtedly, like most of its peers, pharmaceutical companies are facing the dilemma of falling sales due to patent expiration and loss of exclusive property rights.
Therefore, in order to regain the crown of sales, Pfizer's management is now under tremendous pressure. The CEO (CEO) Ian Read needs to be more "strategic" than others to gain recognition from the board.
According to informed sources, Pfizer has two alternative strategies in 2015: to continue large mergers or buy back more stocks.
Where the falls where to get up and continue the pursuit of AstraZeneca, Pfizer
Last year, in the top 10 biomedical events, the most emotional feelings we had were the "Pfizer-AstraZeneca". AstraZeneca, based in London, UK, with research and development headquarters in Sweden, was formed in 1999 by a former Swedish company Astra and former British company, including digestive, cardiovascular, tumor, central nervous, anesthesia and breathing. The therapeutic field provides patients with a variety of pharmaceutical products and is also a leading global pharmaceutical company.
Last year, Pfizer intended to buy AstraZeneca at a price of 55 pounds per share, but AstraZeneca and Pfizer passed three times and five times asking price, unfortunately Pfizer made a compromise and the transaction still fell through.
When Pfizer decided to abandon the acquisition and exit transaction, Neil Woodford, the star fund manager known as "Buffett in the UK" (which re-stocked AstraZeneca and GSK shares) predicted that despite the growth potential of AstraZeneca, Pfizer paid a one-time payment to AstraZeneca's shareholder's compensation is unlikely, but Pfizer will not rule out the acquisition of AstraZeneca again, and he believes that Pfizer's probability of making this decision is half and half.
However, from the current market situation, Pfizer's CEO seems to have moved to love, looking at GlaxoSmithKline (GSK).
GlaxoSmithKline PLC (GSK.L)
Established in December 2000 by GSK Sukang and Shi Ke Bicheng, GSK represents the highest level in the world today in the four major medical fields of anti-infective, central nervous system, respiratory and gastrointestinal/metabolism. The field and anti-cancer drugs are also ranked first in the industry, and of course there is no doubt that the 2013 scandal caused it to suffer some setbacks in 2014.
According to the information disclosed by the SEC, GSK now has a market value of 72.4 billion pounds (about 112.2 billion US dollars), which is slightly higher than Pfizer's valuation of AstraZeneca last year (£69 billion); of course, AstraZeneca's current market value has been Not this price.
AstraZeneca PLC (AZN)
However, there are also rumors that, given the GSK valuation is higher than AstraZeneca, it is not excluded that Pfizer will further increase the price of the acquisition of AstraZeneca.
In addition, from the perspective of Pfizer's own strength, Pfizer's financial report at the end of the third quarter of last year showed that the company's net debt was only 3.6 billion US dollars, which is a total of 78 billion US dollars with its total shareholder equity, so from the balance sheet In terms of perspective, Pfizer has sufficient funds to make price increases.
Double Lumen Endobronchial Tube
Double Lumen PVC Endobronchial Tube with FDA&ISO Certificate
Made of non-toxic medical-grade PVC, transparent, soft and smooth.
Flat design of balloon section can seal effectively and reduce oppression.
With ventilation transition connector, unilateral ventilation can be more convenient.
Description:
A double-lumen Endotracheal tube is a type of endotracheal tube which is used in tracheal intubation during thoracic surgery and other medical conditions to achieve selective, one-sided ventilation of either the right or the left lung.
There are several conditions that may make one-sided lung ventilation necessary. Absolute indications include separation of the right from the left lung to avoid spillage of blood or pus from an infected or bleeding side to the unaffected side. Relative indications include the collapse of one lung and the selective ventilation of the remaining lung in order to facilitate exposure of the anatomical structures to be operated on in thoracic surgeries.
Construction:
Consist of PVC tube, cuff, inflation lumen.
Double Lumen Endobronchial Tube,Disposable Silicone Tube,Dlt Silicone,Pvc Double Lumen Endobronchail Cannula
Hangzhou Trifanz Medical Device Co., Ltd , https://www.cfzmeds.com